CSF2 and cancer: Accordingly, we designed a stakeholder-informed, prospective, pragmatic (ie, conducted in a clinical practice setting, designed for generalizability),15 cluster randomized clinical trial (RCT), the Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER),16 comparing guideline-informed, EHR-enabled, standing order sets for PP-CSF compared with usual care (UC) for patients with breast, lung, and colorectal cancer receiving initial myelosuppressive cancer-directed therapy.